Seoochre

Traditional clinical trials have long served as the cornerstone of medical research, providing essential evidence for evaluating the safety and efficacy of new interventions. However, these trials often encounter significant challenges, including inefficiencies, high costs, logistical complexities, and limited participant diversity. Post the COVID-19 pandemic era, a groundbreaking approach called decentralized clinical trials (DCTs) has emerged as the new normal, harnessing technological advancements to revolutionize the landscape of medical research. This article explores the principles, key

Medicine is the testament to the virtue of human innovation - a collective desire to reduce the burden of disease and an ever evolving journey to enhance the quality of human health. The origin of medicines can be traced back to ancient times when human began to use the natural resources to treat injuries and illness. Highly developed and documented evidences of medicinal practices comes from the world’s most ancient civilisations such as Egypt, India, China and Greece1. Traditional Chinese medicine2, which dates back more than 2,500 years, used a combination of herbs, acupuncture, and other

Artificial intelligence is a field of engineering and science that focus on making intelligent machines. Artificial intelligence is a top technology that is reshaping the pharmaceutical industry's future. For ages, the pharmaceutical industry has been developing cures and treatments. Traditionally, medication design and manufacture took many years, extensive clinical studies, and sky-high prices.This has been changing with the advancement of 21st-century technology. We will see different drug designs, manufacturing, and clinical trials in the future.

Natural Language Processing (NLP), Mach

Bacterial infections are responsible for a wide spectrum of diseases in humans causing significant morbidity and mortality on a global scale. Bacteria can survive in two different forms: free-living planktonic form and biofilm form. Bacterial biofilms are densely packed communities of bacterial cells which are surrounded by a self-produced polymeric matrix. It is reported that over 80% of microbial infections including many chronic diseases in humans are associated with biofilm. Apart from causing havoc in the form of deadly diseases, biofilm bacteria can make medical implants malfunctional o

Many Pharma companies in EU suffer a size problem. When revenues are below 100 M€ is extremely difficult to survive in a market where to renew the portfolio is increasingly costly, as well as to pay the regulatory demands, which grow year by year (environmental regulations, verification, wastes processing, plastics control, etc...). Additionally, the easy solution of playing in the Generics Market does not work anymore, mostly due to the devastating price erosion in major markets (France, Germany, Italy and Spain). These companies use to be a family property and their operations do not exceed

Cannabis plants contain a wide variety of complex compounds including phytocannabinoids, terpenoids and flavonoids, found mainly in the inflorescences. Major phytocannabinoids like CBD and ∆9-THC have beneficial effects on human health. It is well known that variations in their profiles are connected to growth, light quality, humidity, the use of pesticides, harvesting and especially post-harvesting, like improper drying procedures that can facilitate fungal and microbial growth. Mass spectrometry is the tool of choice for the analysis of all these biologically active compounds along with tha

The spleen is an organ found in all vertebrates. It is a large secondary lymphoid organ that primarily functions as a blood filter. The second spleen’s function is immune system surveillance. As a specialized immune organ, the spleen plays a significant role in innate and adaptive immunity. Specifically, the spleen is a crucial organ for peripheral immune tolerance, complementing central immune tolerance. Splenectomy in both study animals and humans results in overwhelming infections with especially, encapsulated bacteria [1]. On the opposite, supporting the immune system with an additional s

A countless number of proteins including growth factors receptors, and cytokines play a pivotal role during the onset and exacerbation of numerous human diseases including cancer, autoimmune and inflammatory disorders.1

Of these proteins, extracellular and membrane-associated proteins represent around 40% of human proteome and they play diversified roles including signal transduction, cell adhesion, cell-cell interaction, and solute transport. Accordingly, the vast majority (ca. 60%) of current therapeutic approaches; such as small molecule inhibitors, oligonucleotide agents and monoclonal

Human and veterinary antimicrobial misuse is one of the cornerstone drivers of antimicrobial resistance (AMR) leading to a rapidly drying up of the antibiotic pipeline. In 2010, the Indian subcontinent was adjudicated to be the world’s largest consumer of antibiotics and hence curbing injudicious use of antibiotics was a must. The current drivers of AMR include veterinary, human, biomedical waste and from innate evolutionary genetical factors leading to the genesis of the menacing MDR, XDR and PDR strains seen worldwide. High grade of evidence now underscores the necessity for antimicrobial s

Cancer is considered as a common name to address a large group comprising more than 100 diseases affecting several parts of the body. All cancers show common characteristics such as the uncontrolled growth and proliferation of abnormal cells, infiltrating and spreading to different tissues and organs throughout the body, and destroying the normal cells and tissues. Cancer can begin in the epithelial tissue and is known as carcinomas, and when it begins in the connective or supportive tissue, they are called sarcomas. The blood cancers are known as leukemias, and when it begins in the plasma c

This article explores the profound impact of bioinformatics in the realm of precision oncology, revolutionising the understanding, diagnosis, and treatment of cancer. Bioinformatics, a multidisciplinary field, bridges the gap between vast biological datasets and meaningful insights, enabling personalised therapies and groundbreaking discoveries. However, challenges in data integrity, reproducibility, and infrastructure must be overcome to fully realise it’s potential. Bioinformatics stands as a beacon of hope, ushering in an era where cancer is decoded at its molecular core, promising improve

While traditional vaccine modalities continue to play an important role, 87% of the respondents intend to focus on mRNA and the majority believe this modality will dominate the future vaccine landscape. Most manufacturers stated an intent to establish capabilities in novel vaccine platforms and indicated that both traditional and modern cell-based vaccines remain important given their proven regulatory record, high efficacy, and generally fewer side effects.

Given the protection offered by the SARS-CoV-2 mRNA vaccines and the accelerated development timelines, it’s no surprise that this mo

Certainly, we are all alike, but we are all unique. And the notion that medication would be used in a way that overlooks those disparities is as absurd as walking to a sneaker store to pick up any old pair of sneakers without first verifying the size. Personalized medicine provides an excellent chance to transform a "one size fits all" strategy to diagnostics, pharmacological therapy, and treatment into a personalised strategy. Nanotechnology advancements have enabled the development of nanomaterials devices for the enhanced diagnosis and tailored treatment of a various range of complicated d

This Biopharmaceutics introduces fundamental concepts, methods, and advances in the areas of dissolution, absorption, and permeability and their key applications in dosage form performance. Case studies are used to discuss the applications of biopharmaceutic strategies in the development of successful drugs, with a specific focus on the applications of biopharmaceutic strategies in the development of successful drugs. The book presents an integrated view in linking pharmaceutic to the biological consequences of drug products and leverages those for decision making in drug development. The Bio

The earliest example of in vivo expression of exogenous mRNA is by direct intramuscular injection in mice without the aid of a delivery vehicle. The current state of the art for therapeutic nucleic acid delivery is lipid nanoparticles (LNP), which are composed of cholesterol, a helper lipid, a PEGylated lipid and an ionizable amine-containing lipid. The liver is the primary organ of LNP accumulation following intravenous administration and is also observed to varying degrees following intramuscular and subcutaneous routes. Delivery of nucleic acid to hepatocytes by LNP has therapeutic potenti

In a clinical trial, actors admit specific interventions according to the exploration plan or protocol created by the investigators. These interventions may be medical products, similar as medicines or bias; procedures; or changes to actors' geste , similar as diet [1]. Clinical trials may compare a new medical approach to a standard bone that's formerly available, to a placebo that contains no active constituents, or to no intervention. Some clinical trials compare interventions that are formerly available to each other. When a new product or approach is being studied, it isn't generally kno

The drug business has various strange qualities that make it very different from individuals' thought process of as industry. Its additionally an industry packed with logical inconsistencies; for instance, notwithstanding the undisputed reality that for more than a century the business has made a major contribution to human prosperity and the decrease of chronic sickness and suffering, it is still routinely recognized bygeneral society in assessment reviews as one of the most un-confided in ventures, frequently being contrasted horribly with the atomic business. It is without a doubt perhaps

Pharmaceutical development is the identification and evaluation of cycles needs to change over a functioning drug fixing into a medication item reasonable for its expected reason. In the beginning phases of medication advancement, this will be for limited scope assembling of item to be utilized in clinical preliminaries. In the event that the preliminaries are fruitful, the cycle should be refreshed and improved to make it reasonable for make on a business scale. The drug improvement process starts by estimating the properties of the medication substance, and recognizing the basic quality cre

Globally, cancer is the second most prevalent healthcare issue, following cardiovascular. Conventional methods such as chemotherapy and radiotherapy have several detrimental side effects without guaranteed permanent recovery. In the last few decades, efforts have been made by introducing nanotechnology to cancer therapeutics. Owing to the size range of the nanomaterials i.e., 1 nm to 500 nm (1 nanometre is one-billionth of a meter) with remarkable physiological properties, provided scope for diagnosis at early stage and therapeutics at a cellular level. Recently, nanoengineering of the struct

The use of time-to-event analysis is common in clinical research. The interpretation of time-to-event analysis can often be misleading. Beginners and early career researchers struggle to grasp the concepts and nuances in a time-to-event analysis. The concepts of censoring, truncation, and bias related to time-to-event analysis are essential for interpreting and applying findings. Regarding bias, lead-time bias and length-time bias are the most important. Lead-time and length-time bias are critical in analysing clinical trials involving time-to-event analysis. This article aims to simplify the